Terms: = Ovarian cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
245 results:
1. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract] [Full Text] [Related]
2. Randomized Phase II Study of Gemcitabine With or Without atr Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract] [Full Text] [Related]
3. Patient Location and Disparities in Access to Fertility Preservation for Women With Gynecologic or Breast cancer.
Kanbergs A; Jorgensen K; Agusti N; Viveros-Carreño D; Wu CF; Nitecki R; Harris JA; Woodard T; Ramphul R; Rauh-Hain JA
Obstet Gynecol; 2024 Jun; 143(6):824-834. PubMed ID: 38574368
[TBL] [Abstract] [Full Text] [Related]
4. AKTing on R Loops Makes for an atractive Target in ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
5. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (atr) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
[TBL] [Abstract] [Full Text] [Related]
6. AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in ovarian cancer.
Huang TT; Chiang CY; Nair JR; Wilson KM; Cheng K; Lee JM
Cancer Res; 2024 Mar; 84(6):887-904. PubMed ID: 38241710
[TBL] [Abstract] [Full Text] [Related]
7. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
8. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y; Dobrolecki LE; Sallas C; Zhang X; Kerr TD; Bisht D; Wang Y; Awasthi S; Kaundal B; Wu S; Peng W; Mendillo ML; Lu Y; Jeter CR; Peng G; Liu J; Westin SN; Sood AK; Lewis MT; Das J; Yi SS; Bedford MT; McGrail DJ; Sahni N
Cell Rep Med; 2023 Dec; 4(12):101326. PubMed ID: 38118413
[TBL] [Abstract] [Full Text] [Related]
9. Targeted inhibition of the atr/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract] [Full Text] [Related]
10. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors.
Zhang C; Peng K; Liu Q; Huang Q; Liu T
Crit Rev Oncol Hematol; 2024 Jan; 193():104233. PubMed ID: 38103761
[TBL] [Abstract] [Full Text] [Related]
11. Programmable DNA Hydrogel Assisting Microcrystal Formulations for Sustained Locoregional Drug Delivery in Surgical Residual Tumor Lesions and Lymph Node Metastasis.
Zhang ZJ; Zhou Y; Tong H; Sun XC; Lv ZC; Yong JK; Wu YC; Xiang XL; Ding F; Zuo XL; Li F; Xia Q; Feng H; Fan CH
Adv Healthc Mater; 2024 Apr; 13(11):e2303762. PubMed ID: 38047767
[TBL] [Abstract] [Full Text] [Related]
12. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in ovarian cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract] [Full Text] [Related]
13. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract] [Full Text] [Related]
14. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
15. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract] [Full Text] [Related]
16. DNA2 Nuclease Inhibition Confers Synthetic Lethality in cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
[TBL] [Abstract] [Full Text] [Related]
17. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer.
Ren L; Qing X; Wei J; Mo H; Liu Y; Zhi Y; Lu W; Zheng M; Zhang W; Chen Y; Zhang Y; Pan T; Zhong Q; Li R; Zhang X; Ruan X; Yu R; Li J
Cell Death Dis; 2023 Aug; 14(8):568. PubMed ID: 37633920
[TBL] [Abstract] [Full Text] [Related]
18. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox N; Dumont M; González-Neira A; Carvalho S; Joly Beauparlant C; Crotti M; Luccarini C; Soucy P; Dubois S; Nuñez-Torres R; Pita G; Gardner EJ; Dennis J; Alonso MR; Álvarez N; Baynes C; Collin-Deschesnes AC; Desjardins S; Becher H; Behrens S; Bolla MK; Castelao JE; Chang-Claude J; Cornelissen S; Dörk T; Engel C; Gago-Dominguez M; Guénel P; Hadjisavvas A; Hahnen E; Hartman M; Herráez B; ; Jung A; Keeman R; Kiechle M; Li J; Loizidou MA; Lush M; Michailidou K; Panayiotidis MI; Sim X; Teo SH; Tyrer JP; van der Kolk LE; Wahlström C; Wang Q; Perry JRB; Benitez J; Schmidt MK; Schmutzler RK; Pharoah PDP; Droit A; Dunning AM; Kvist A; Devilee P; Easton DF; Simard J
Nat Genet; 2023 Sep; 55(9):1435-1439. PubMed ID: 37592023
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
20. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
[TBL] [Abstract] [Full Text] [Related]
[Next]
